OncoMatch/Clinical Trials/NCT06514313
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.
Is NCT06514313 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine and Temozolomide+Irinotecan+Vincristine for soft tissue sarcoma.
Treatment: Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine · Temozolomide+Irinotecan+Vincristine — Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine (VIM) in the treatment of relapsed/refractory soft tissue sarcoma in children.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Prior therapy
Cannot have received: anthracycline (mitoxantrone, mitoxantrone liposomes, adriamycin)
Exception: adriamycin cumulative dose ≤ 360 mg/m^2 and no cardiac disease caused by anthracyclines
Once received mitoxantrone or mitoxantrone liposomes. Previous treatment with adriamycin or other anthracyclines with a total cumulative dose of adriamycin > 360 mg/m^2; Or patients with cardiac disease caused by previous anthracyclines.
Cannot have received: VIT chemotherapy (irinotecan, temozolomide, vincristine)
Patients who had received previous VIT (irinotecan + temozolomide + vincristine) chemotherapy.
Lab requirements
Blood counts
Good blood and organ function.
Kidney function
Good blood and organ function.
Liver function
Good blood and organ function.
Cardiac function
LVEF ≥ 50% by cardiac COLOR ultrasound; ECG suggests no myocardial ischemia; no history of arrhythmia requiring drug intervention before enrollment.
Heart function: a) Cardiac COLOR ultrasound detection LVEF≥ 50%; b) ECG suggests no myocardial ischemia; c) No history of arrhythmia requiring drug intervention before enrollment. Good blood and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify